The clinical and economic impact of pneumococcal conjugate vaccine associated herd immunity in Canada

References

• Bigham M, Hoefer M. Comparing benefits and risks of immunization. Canadian Journal of Public Health 2001; 92: 173–177.
   PubMedGoogle Scholar
• Barreto L, Rutty CJ. The speckled monster: Canada, smallpox and its eradication. Canadian Journal of Public Health 2002; 93: 1–20.
   Google Scholar
• Varughese PV, Carter AO, Acres SE, Furesz J. Eradication of indigenous poliomyelitis in Canada: impact of immunization strategies. Canadian Journal of Public Health 1989; 80: 363–368.
   PubMedGoogle Scholar
• Acres SE, Varughese PV. Impact of vaccination on selected diseases in Canada. Canadian Medical Association Journal 1985; 132: 635–639.
   PubMedGoogle Scholar
• Scheifele DW. Recent trends in pediatric Haemophilus influenzae type B infections in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control. Canadian Medical Association Journal 1996; 154: 1041–1047.
   Web of Science ®Google Scholar
• MacDonald N. Routine immunization schedule: Update 2004. Paediatrics and Child Health 2004; 9: 17–20.
   PubMedGoogle Scholar
• National Advisory Committee on Immunization. Statement on recommended use of pneumococcal conjugate vaccine. Canada Communicable Disease Report. 15 January 2002.
   Google Scholar
• Bjornson GL, Scheifele DW, Halperin SA et al. Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. Pediatric Infectious Disease Journal 2002; 21: 947–950.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatric Infectious Disease Journal 2000; 19: 187–195.
   PubMed Web of Science ®Google Scholar
• Schiefele D, Halperin S, Pelletier L, Talbot J. Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT). Clinical Infectious Diseases 2000; 31: 58–64.
   PubMedGoogle Scholar
• Canadian Pediatric Society Statement. Pneumococcal vaccine for children. Paediatrics and Child Health 2002; 6: 214–217.
   Google Scholar
• Lebel MH, Kellner JD, Ford Jones EL et al. A health economic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clinical Infectious Diseases 2003; 36: 259–268.
   PubMed Web of Science ®Google Scholar
• O’Brien L, Dagan R. The potential indirect effect of conjugate pneumococcal vaccine. Vaccine 2003; 21: 1815–1825.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein- polysaccharide conjugate vaccine. New England Journal of Medicine 2003; 348: 1737–1746.
   PubMedGoogle Scholar
• McGeer A, Green K, Landry L et al. Assesssing the potential impact of vaccination programs on invasive pneumococcal disease: Data from population-based surveillance. Canadian Journal of Infectious Disease 1999; 10: 24–26.
   Google Scholar
• Stratton KR, Durch JS, Lawrence RS. Institute of Medicine. Vaccines for the 21st century: A tool for decision-making. National Academy of Sciences Press 2001: 313–322.
   Google Scholar
• Health Canada. Preventing pneumococcal disease: A Canadian consensus conference. Canada Communicable Disease Report 1999; 25: 1–13.
   Google Scholar
• Hofman J, Cetron MS, Farley MM et al. The prevalence of drug resistant Steptococcus pneumoniae in Atlanta. New England Journal of Medicine 1995; 333: 481–486.
   PubMedGoogle Scholar
• US Census Bureau, Population Division. Table NA-EST2002-01 – National population estimates: 1 April 2000 to 1 July 2002. 31 December 2002.
   Google Scholar
• Statistics Canada. Population estimates by age and sex. Table 051–0001. 2002.
   Google Scholar
• Health Care Financing and Administration. Health Care Financing Review: HCFA Pub. No. 03348. Baltimore, MD: US Department of Health and Human Services, 1995.
   Google Scholar
• Bank of Canada. Currency Converter Calculator. http://www.bank-banque- canada.ca/en/exchform.htm. Date accessed: September 2003.
   Google Scholar
• Sahr RC. Inflation conversion factors in 2000 dollars from 1800 to 2014. Oregon State University. http://oregonstate.edu/ dept/pol_sci/fac/sahr/sahr.htm. Date accessed: September 2003.
   Google Scholar
• Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. British Medical Journal 1999; 319: 635–658.
   PubMed Web of Science ®Google Scholar
• Moore D, Bigham M, Patrick D. Modeling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Canada Communicable Disease Report 2003; 29: 97–104.
   PubMedGoogle Scholar
• De Waals P, Petit G, Erickson LJ et al. Benefits and costs of immunizing children with pneumococcal conjugate vaccine in Canada. Vaccine 2003; 21: 3757–3764.
   PubMedGoogle Scholar
• Schiefele D. New vaccines and the rising costs of caring. Pediatrics and Child Health 2000; 5: 371–372.
   PubMedGoogle Scholar
• Dagan R, Fraser D. Conjugate pneumococcal vaccine and antibiotic- resistant Streptococcus pneumoniae: herd immunity and reduction of otitis morbidity. Pediatric Infectious Disease Journal 2000; 19: S79–S87.
   PubMed Web of Science ®Google Scholar
• Whitney CG. The potential of pneumococcal conjugate vaccines for children. Pediatric Infectious Disease Journal 2002; 21: 961–970.
   PubMedGoogle Scholar
• Flannery B, Schrag S, Bennett NM et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumonia infections. Journal of the American Medical Association 2004; 291: 2197–2203.
   PubMedGoogle Scholar
• Centers for Disease Control. Influenza and pneumococcal vaccination levels among persons aged ≥65 years. United States 2001. Morbidity and Mortality Weekly Report 2002; 51: 1019–1024.
   PubMedGoogle Scholar
• Squires SG, Macey JF, Tam T. Progress towards Canadian target rates for influenza and pneumoccocal immunizations. Canada Communicable Disease Report 2001; 27: 90–91.
   PubMedGoogle Scholar
• Conseil d’Evaluation des Technologies de la Sante du Quebec. Cost-effectiveness and cost-utility of a pneumococcal immunization program in Quebec. National Library of Canada. October 1999.
   Google Scholar
• Lave JR, Chyongchiou JL, Fine MJ, Paul Hughes-Cromwick MA. The costs of treating patients with community acquired pneumonia. Seminars in Respiratory and Critical Care Medicine 1999; 20: 189–197.
   Google Scholar